StreetInsider.com News Articles

Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform

Wed, 23 Sep 2026 06:55:23 -0400

(Updated - September 23, 2026 6:55 AM EDT)

Oppenheimer analyst Les Sulewski assumes coverage on Inova Technology, Inc. (NASDAQ: INVA) with a Outperform rating and a price target of $35.00.

The analyst comments "We assume coverage of Innoviva with an Outperform rating and $35 PT. We believe the market values INVA primarily as a declining respiratory royalty company while assigning limited credit to a fast-growing critical care and infectious disease platform and strategic healthcare assets. Durable Breo/Relvar and Anoro royalties fund IST growth, BD, strategic investments, and share repurchases. Xacduro and Giapreza lead current growth, while Zevtera, Nuzolvence, ex-US expansion, and potential

Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform

Wed, 23 Sep 2026 06:55:23 -0400

(Updated - September 23, 2026 6:55 AM EDT)

Oppenheimer analyst Les Sulewski assumes coverage on Inova Technology, Inc. (NASDAQ: INVA) with a Outperform rating and a price target of $35.00.

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Inova Technology (INVA) Reiterated at Overweight by Cantor Fitzgerald Post Webinar With CEO, CFO

Fri, 21 Aug 2026 08:35:20 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $34.00 price target on Inova Technology, Inc. (NASDAQ: INVA).

The analyst commented, "We hosted Innoviva for a broad update via webinar this week. The replay provides a great primer on Innoviva's history, as the company evolved from a royalty-only business into a diversified biopharma with a growing Innoviva Specialty Therapeutics (IST) commercial platform and a portfolio of strategic healthcare assets. INVA is profitably growing an underlying commercial business with a >50% CAGR historically, and the stock (~$1.5B market cap) is trading at < 8x TTM revenue (~$212M TTM) with respect to

Innoviva unit's three antibiotics named Prix Galien USA finalists

Tue, 11 Aug 2026 16:06:12 -0400

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that three of its infectious disease drugs — Xacduro, Zevtera, and Nuzolvence — have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category, according to a press release.

The company said this marks the third consecutive year one of its products has been recognized as a finalist by the Galien Foundation. The 2026 award winners are scheduled to be announced at a ceremony on October 29, 2026, in New York City.

Xacduro (sulbactam/durlobactam for injection) was approved by the FDA in May 2023 for

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award